Loading...
Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies
CPX‐351, a dual‐drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy‐related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia‐related changes. Population pharmacokinetics analy...
Na minha lista:
| Udgivet i: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6590377/ https://ncbi.nlm.nih.gov/pubmed/30566230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1366 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|